Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals

Mycoses

Volumn 55, Issue 6, 2012, Pages 514-520

  Rieger, C T ^a   Cornely, O A ^b   Hoppe Tichy, T ^c   Kiehl, M ^d   Knoth, H ^e   Thalheimer, M ^c   Schuler, U ^e   Ullmann, A J ^f   Ehlken, B ^g   Ostermann, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Clinical Center Frankfurt/Oder   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g IQVIA   (United States)

Author keywords

Cost analyses; Invasive fungal disease

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; FEVER; GEOTRICHOSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; PARENTERAL NUTRITION; PRIORITY JOURNAL; SYSTEMIC MYCOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; LENGTH OF STAY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOSES; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84867495480     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02193.x     Document Type: Article

References (21)

1. Bow E. J. Considerations in the approach to invasive fungal infection in patients with haematological malignancies. Br J Haematol 2008; 140: 133-52.
2. Maschmeyer G, Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 2008; 31: 193-7.
3. Gratwohl A., Brand R., Frassoni F. et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-69.
4. Marr K. A., Carter R. A., Boeckh M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
5. Lin S. J., Schranz J., Teutsch S. M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
6. Herbrecht R., Denning D. W., Patterson T. F. et al. Voriconazole vs. amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
7. Reboli A. C., Rotstein C., Pappas P. G. et al. Anidulafungin vs. fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
8. Cornely O. A., Maertens J., Winston D. J. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-59.
9. Walsh T. J., Teppler H., Donowitz G. R. et al. Caspofungin vs. liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
10. Slobbe L., Polinder S., Doorduijn J. K. et al. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Clin Infect Dis 2008; 47: 1507-12.
11. Wingard J. R., Herbrecht R., Mauskopf J., Schlamm H. T., Marciniak A., Roberts C. S. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007; 9: 182-8.
12. Rote Liste® Service GmbH (ed) Rote Liste 2007. Germany: Editio Cantor Verlag, Frankfurt/ Main, 2007.
13. Deutsche Krankenhausgesellschaft (ed) DKG-NT Band I / BG-T. Tarif der Deutschen Krankenhausgesellschaft zugleich vereinbarter Tarif für die Abrechnung mit den gesetzlichen Unfallversicherungsträgern. 31. Stuttgart, Deutschland 31. Auflage: aktualisierte Auflage, Kohlhammer W. Verlag GmbH, 2007.
14. Dixon S., McKeen E., Tabberer M., Paisley S. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics 2004; 22: 421-33.
15. Jansen J. P., Kern W. V., Cornely O. A. et al. Economic evaluation of voriconazole vs. conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health 2006; 9: 12-23.
16. Kaskel P., Tuschy S., Wagner A. et al. Economic evaluation of caspofungin vs. liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol 2008; 87: 311-19.
17. Collins C. D., Ellis J. J., Kaul D. R. Comparative cost-effectiveness of posaconazole vs. fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm 2008; 65: 2237-43.
18. de Vries R., Daenen S., Tolley K. et al. Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections. Pharmacoeconomics 2008; 26: 75-90.
19. O'Sullivan A. K., Pandya A., Papadopoulos G. et al. Cost-Effectiveness of Posaconazole vs. Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infections among Neutropenic Patients in the United States. Value Health 2009; 12: 666-73.
20. Stam W. B., O'Sullivan A. K., Rijnders B. et al. Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 2008; 81: 467-74.
21. Schiffer C. A., Anderson K. C., Bennett C. L. et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.